You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
Company officials credited investments in information technology, as well as R&D for RT-PCR-based tests, with driving up the firm's billable testing numbers.
The genetic testing company said its orders for traditional tests have also rebounded and are on track for growth in the second half of 2020.
The seven technologies feature different methods, including CRISPR and microfluidics, and can be performed in many settings and with a variety of sample types.
FBB Biomed, cofounded by a diagnostics industry veteran, is attempting to develop a blood RNA test to predict COVID-19 disease severity.
In a study published last month, Mammoth demonstrated the technology's sensitivity, specificity, and speed compared to PCR-based COVID-19 testing.
Children's Hospital Los Angeles used a SARS-CoV-2 sequencing panel to determine if patients had become infected from the same source as healthcare workers.
Fulgent saw a 75 percent increase year over year in billable tests, leading to revenues of $7.8 million. It also withdrew its 2020 full-year revenue guidance.
The researchers said their assay can be run in 30 to 45 minutes, with 95 percent positive predictive agreement and 100 percent negative predictive agreement.
The company, known for clinical chemistry and molecular biology diagnostic kits, is currently working on two test kits for SARS-CoV-2.
Labrador Diagnostics, a firm controlled by an investment group that acquired Theranos' IP, alleged BioFire's FilmArray products infringe two patents.